KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Free Cash Flow: 2017-2025

Historic Free Cash Flow for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to -$12.9 million.

  • Aquestive Therapeutics' Free Cash Flow fell 7.73% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.9 million, marking a year-over-year decrease of 48.21%. This contributed to the annual value of -$35.9 million for FY2024, which is 387.02% down from last year.
  • Aquestive Therapeutics' Free Cash Flow amounted to -$12.9 million in Q3 2025, which was down 60.63% from -$8.0 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Free Cash Flow high stood at $8.8 million for Q1 2023, and its period low was -$23.5 million during Q1 2025.
  • In the last 3 years, Aquestive Therapeutics' Free Cash Flow had a median value of -$8.0 million in 2025 and averaged -$8.0 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first soared by 197.63% in 2022, then crashed by 378.78% in 2024.
  • Aquestive Therapeutics' Free Cash Flow (Quarterly) stood at -$8.6 million in 2021, then skyrocketed by 197.63% to $8.4 million in 2022, then crashed by 159.09% to -$5.0 million in 2023, then crashed by 31.18% to -$6.5 million in 2024, then decreased by 7.73% to -$12.9 million in 2025.
  • Its Free Cash Flow stands at -$12.9 million for Q3 2025, versus -$8.0 million for Q2 2025 and -$23.5 million for Q1 2025.